What is the appropriate dosing, monitoring, and reversal protocol for an unfractionated heparin drip?

Unfractionated Heparin Drip Protocol

For therapeutic anticoagulation with unfractionated heparin (UFH), use weight-based dosing with an 80 units/kg IV bolus followed by 18 units/kg/hour continuous infusion, targeting an aPTT of 1.5-2.5 times control or anti-Xa level of 0.30-0.70 IU/mL, with monitoring every 4 hours initially. 1

Initial Dosing

The FDA-approved weight-based regimen is superior to fixed dosing:

• Bolus: 80 units/kg IV (maximum 10,000 units for most protocols)
• Infusion: 18 units/kg/hour continuous IV 1

This weight-based approach achieves therapeutic levels faster and reduces recurrent thromboembolism compared to fixed-dose regimens 2. The evidence from Raschke et al. demonstrated significantly lower recurrence rates with weight-adjusted dosing because patients received higher doses within the first 24 hours 2.

Alternative dosing (less preferred): 5,000-unit bolus followed by at least 32,000 units/day (approximately 1,333 units/hour minimum) 2

Context-Specific Dosing Adjustments

For acute coronary syndromes, use lower doses:

• Bolus: 60-70 units/kg (maximum 5,000 units)
• Infusion: 12-15 units/kg/hour (maximum 1,000 units/hour) 2

For pediatric patients:

• Initial: 75-100 units/kg IV bolus over 10 minutes
• Infants: 25-30 units/kg/hour (infants <2 months require highest doses, averaging 28 units/kg/hour)
• Children >1 year: 18-20 units/kg/hour
• Target aPTT: 60-85 seconds 1

Monitoring Protocol

Laboratory Testing Schedule

Initial phase (first 24-48 hours):

• Check aPTT or anti-Xa level every 4 hours after starting infusion 1
• Continue every 4 hours until two consecutive therapeutic values achieved
• Then extend to every 6-12 hours once stable

Ongoing monitoring:

• Daily platelet counts (to detect heparin-induced thrombocytopenia)
• Daily hematocrit
• Periodic stool guaiac testing 1

Therapeutic Targets

aPTT method: 1.5-2.5 times control value (or 1.5-2.0 times baseline) 1

Anti-Xa assay (preferred when available): 0.30-0.70 IU/mL 3

The anti-Xa assay is increasingly favored because it is less affected by pre-analytical variables and biological interferences that plague aPTT testing 3. Recent ISTH guidance (2026) recommends anti-Xa over aPTT due to superior standardization 3. However, aPTT remains widely used due to availability and familiarity 4.

Critical Monitoring Considerations

Pre-analytical factors that affect results:

• Centrifuge blood within 1 hour of collection
• Test within 10 minutes of centrifugation (1 hour acceptable)
• Use standard 3.2% (109 mM) buffered trisodium citrate tubes 3

Common pitfall: The aPTT therapeutic range of 1.5-2.5 times control is based on weak evidence from a single 1970s retrospective study and has never been validated in randomized trials 2, 4. Despite this limitation, it remains the standard because achieving therapeutic aPTT within 24 hours correlates with reduced mortality 2.

Dose Adjustment

When aPTT or anti-Xa results return:

• Adjust infusion rate within 2 hours of receiving laboratory result 5
• Use a standardized nomogram for adjustments (institution-specific)
• Recheck levels 4 hours after any rate change 1

Key principle: UFH dose appears more important than achieving specific aPTT values for clinical efficacy 4. Ensure adequate initial dosing rather than obsessing over precise aPTT targets.

Reversal Protocol

For life-threatening bleeding or emergent surgery requiring immediate reversal:

Protamine sulfate is the antidote:

• Dose: 1 mg protamine neutralizes approximately 100 units of heparin
• Maximum rate: 50 mg over 10 minutes (give slowly to avoid anaphylactoid reactions)
• Timing matters: The required protamine dose decreases as heparin is metabolized (heparin half-life approximately 30 minutes) 1

Dosing calculation based on timing:

• If heparin infusion just stopped: Give protamine based on total heparin received in last 2-3 hours
• If 30-60 minutes since stopping: Reduce protamine dose by 50%
• If >2 hours since stopping: May need minimal or no protamine

Monitoring reversal:

• Check thrombin time immediately and 1 hour after protamine administration 6
• Have resuscitation equipment immediately available (anaphylaxis risk) 1

Critical warning: Fatal anaphylactoid reactions can occur with protamine, particularly in patients with fish allergies, prior protamine exposure, or NPH insulin use 1.

Transition to Oral Anticoagulation

Converting to warfarin:

• Continue full-dose heparin for several days
• Start warfarin on day 1
• Overlap until INR therapeutic (≥2.0) for 24 hours on two consecutive days
• Do NOT taper heparin—stop abruptly once INR therapeutic 1

Converting to DOACs (apixaban, rivaroxaban, dabigatran, edoxaban):

• Stop heparin infusion immediately when giving first DOAC dose
• No overlap required 1

Special Situations

Cardiovascular surgery: Requires much higher doses (300-400 units/kg for cardiopulmonary bypass) 1

Extracorporeal dialysis: 25-30 units/kg bolus followed by 1,500-2,000 units/hour infusion 1

Perioperative bridging: When bridging warfarin, use therapeutic-dose UFH targeting aPTT 1.5-2.0 times control or anti-Xa 0.35-0.70 IU/mL 7

Key Practice Points

• Do not admix UFH with other drugs in the same line 1
• Inspect solution for particulates/cloudiness before administration 1
• Use non-vented infusion sets 1
• Pharmacy monitoring significantly improves protocol adherence and appropriate dose adjustments 5
• Consider LMWH instead of UFH for most VTE cases—it has superior efficacy, safety profile, and requires no monitoring 8

Major limitation: Despite decades of use, UFH monitoring lacks robust evidence-based therapeutic ranges, and significant practice variation exists globally 3, 9. The weight-based dosing and early achievement of therapeutic levels matter more than the specific monitoring method chosen.